GANX (gaintherapeutics.com) Accounting Capitalization

Public company logo of gaintherapeutics.com (GANX)

Market fluctuations in Gain Therapeutics, Inc. (GANX) shares confirm confidence in a team whose scientific foundation in conformational therapy is accelerating clinical trials. The business optimizes drug development through digital systems, mitigating risks via external contractors, which maintains profitability at 0.01. SEE-Tx technology enables the correction of protein malfunctions, creating the potential for exclusive market control over Gaucher disease therapy.

GANX (gaintherapeutics.com) Company Book Value history from 07/04/2022 to 10/30/2026

Gain Therapeutics - analytical breakdowns and key metrics (GANX)

- share price and consensus valuation forecast:
Share Price gaintherapeutics.com|GANX - Consensus Target
- business market valuation indicators:
Market Capitalization Gain Therapeutics Inc.|GANX - Real Price to Acquire Entire Company
- book capitalization indicators:
Book Price of a Share Gain Therapeutics|GANX - Company Book Value|Market Value to Book Value gaintherapeutics.com|GANX - Company Total Assets
- debt burden and liquidity indicators:
Debt to Capital Gain Therapeutics, Inc.|GANX - Long-Term Debt to Capital|Short-Term Debt to Capital Gain Therapeutics Inc.|GANX - Company Total Debt|Debt to Book Capital Gain Therapeutics Inc.|GANX - Company Long-Term Debt|Company Current Liabilities Gain Therapeutics|Immediate Liquidity gaintherapeutics.com
- net income and valuation multiples indicators:
GANX - Company Net Income
Fundamental valuation:gaintherapeutics.com (GANX)
Core merchandise of Gain Therapeutics

Book value capitalization serves as a key filter during asset stress testing, allowing for the assessment of the real value of net assets in dynamics relative to market quotes. By analyzing the structure of book value capitalization, an investor can see the ratio of book value to market demand, which for Gain Therapeutics, Inc. (GANX) confirms the effectiveness of monetizing the SEE-Tx AI platform through exclusive licensing agreements with global pharma behemoths.

Competitor analysis

HCA (HCA Healthcare, Inc.) - Accounting Capitalization|THC (Tenet Healthcare) - Company Net Assets|Accounting Capitalization FMS|Company Net Assets SOLV|EHC (Encompass Health Corp) - Total Net Assets|Company Book Value Universal Health Services (UHS)|DVA (DaVita Corp) - Accounting Value of Company|Book Capitalization RDNT (RadNet, Inc.)|optioncarehealth.com (OPCH) - Total Stockholders' Equity|Surgery Partners - Book Capitalization|PINC - Book Capitalization|EYE (National Vision Corp) - Company Net Assets|PGNY: Total Net Assets|Company Book Value Ardent Health Partners, Inc.|Company Net Assets selectmedical.com (SEM)|Book Capitalization ASTH|MD - Total Stockholders' Equity|Company Book Value U.S. Physical Therapy, Inc. USPH|PNTG: Accounting Capitalization|ORGO: Company Net Assets|nutexhealth.com - Total Net Assets|AUNA: Book Capitalization|Book Value of Business SBC Medical Group Inc SBC|EOLS (Jeuveau) - Book Capitalization|Book Capitalization Community Health Corp|Book Capitalization SKIN|Book Valuation of Business mediwound.com|Company Book Value biote Corp BTMD|JYNT: Accounting Capitalization|DCGO: Company Net Assets|Accounting Value of Company PIII (P3 Health Partners Inc.)|EUDA (EUDA Health) - Company Net Assets|BMGL: Total Net Assets|CLGN (CollPlant) - Book Capitalization|CUPR: Accounting Value of Company|Book Capitalization CCM|AMS - Total Stockholders' Equity|Company Book Value MEDIROM MRM|Accounting Value of Company ALBT|DIH Holding - Book Capitalization|XAGE - Book Capitalization|NewGenIvf Group Ltd (NIVF) - Company Book Value|Net Asset Value ATIP (ATI Physical Therapy, Inc.)|CMAX (CareMax, Inc.) - Book Capitalization|Total Stockholders' Equity kindlymd.com KDLY|Company Net Assets MODV (ModivCare)|Book Capitalization Novo Integrated Sciences Inc (NVOS)|SunLink Health Systems, Inc. - Company Net Assets|Total Net Assets BACK (IMAC Corp)